Bio-Rad Laboratories Inc
Company Profile
Business description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Contact
1000 Alfred Nobel Drive
HerculesCA94547
USAT: +1 510 724-7000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
7,700
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,255.66 | 57.46 | -0.69% |
| DAX 40 | 25,252.99 | 99.40 | -0.39% |
| Dow JONES (US) | 49,387.86 | 54.58 | -0.11% |
| FTSE 100 | 10,228.06 | 10.88 | -0.11% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,575.63 | 45.61 | 0.19% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,949.26 | 4.79 | 0.07% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |